Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.10 USD
Change Today +0.0049 / 4.90%
Volume 383.6K
GTHP On Other Exchanges
Symbol
Exchange
OTC BB
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

guided therapeutics inc (GTHP) Snapshot

Open
$0.10
Previous Close
$0.10
Day High
$0.10
Day Low
$0.09
52 Week High
05/28/14 - $0.55
52 Week Low
05/20/15 - $0.07
Market Cap
11.2M
Average Volume 10 Days
787.5K
EPS TTM
$-0.12
Shares Outstanding
106.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GUIDED THERAPEUTICS INC (GTHP)

Related News

No related news articles were found.

guided therapeutics inc (GTHP) Related Businessweek News

No Related Businessweek News Found

guided therapeutics inc (GTHP) Details

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. The company primarily develops LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected or emanating from the cervix. It is also developing a non-invasive test for the early detection of esophageal cancer using the technology platform. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was founded in 1992 and is based in Norcross, Georgia.

38 Employees
Last Reported Date: 05/7/15
Founded in 1992

guided therapeutics inc (GTHP) Top Compensated Officers

Chief Executive Officer, President, Acting Ch...
Total Annual Compensation: $450.0K
Senior Vice President of Engineering and Secr...
Total Annual Compensation: $203.0K
Chief Scientific Officer
Total Annual Compensation: $277.7K
Compensation as of Fiscal Year 2014.

guided therapeutics inc (GTHP) Key Developments

FDA Completes Review of Guided Therapeutics’ LuViva Advanced Cervical Scan PMA Application

Guided Therapeutics Inc. announced that it has received notification from the U.S. Food and Drug Administration regarding the pre-market approval (PMA) application for the LuViva Advanced Cervical Scan. In its most recent communication, FDA advised the company that its PMA amendment, filed in July 2014, was not approvable in its current form. While the agency advised the company that more patient data would likely be necessary to amend the current application, the agency also stated its willingness to consider alternative approaches to move the product to approvable form. FDA and the company intend to meet to discuss the plan for submission of an updated amendment and ultimately reach agreement on steps forward for a path to approval to resolve any remaining data analysis issues. At this meeting, the company intends to present additional U.S. and international data that the company believes will further support the clinical benefits of LuViva. The company currently has regulatory approval to sell LuViva in Europe with the Edition 3 CE mark, and has marketing approvals from COFEPRIS in Mexico, Health Canada and Singapore Health Sciences Authority, among others. Additionally, expansion efforts are ongoing in the Middle East, Asia and Latin America.

Guided Therapeutics, Inc - Special Call

To discuss the FDA response on the pre-market approval (PMA) application for the LuViva® Advanced Cervical Scan

Guided Therapeutics, Inc Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Full Year of 2015

Guided Therapeutics Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company announced that revenue and other income was approximately $142,000, including approximately $127,000 in sales of LuViva Advanced Cervical Scan devices and disposables. The net loss attributable to common stockholders for the first quarter of 2015 was approximately $1.2 million, or $0.01 per share, compared to approximately $1.6 million, or $0.02 per share, in the first quarter of 2014. Contract and grant revenue was $15,000 compared to $19,000 a year ago. Operating loss was $1,473,000 compared to $2,079,000 a year ago. Net loss was $1,245,000 compared to $1,562,000 a year ago. The company provided earnings guidance for the full year of 2015. For the period, the company expects revenue for 2015 to be heavily weighted to the latter half of the year, consistent with the quarterly forecasts from the distributors. The company continues to project sales of $3 million for 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GTHP:US $0.10 USD +0.0049

GTHP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hologic Inc $35.05 USD +0.09
View Industry Companies
 

Industry Analysis

GTHP

Industry Average

Valuation GTHP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GUIDED THERAPEUTICS INC, please visit www.guidedinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.